Immunocore Holdings Balance Sheet Health
Financial Health criteria checks 6/6
Immunocore Holdings has a total shareholder equity of $377.8M and total debt of $438.7M, which brings its debt-to-equity ratio to 116.1%. Its total assets and total liabilities are $1.1B and $706.8M respectively.
Key information
116.1%
Debt to equity ratio
US$438.70m
Debt
| Interest coverage ratio | n/a |
| Cash | US$901.28m |
| Equity | US$377.83m |
| Total liabilities | US$706.81m |
| Total assets | US$1.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6YG's short term assets ($1.0B) exceed its short term liabilities ($266.2M).
Long Term Liabilities: 6YG's short term assets ($1.0B) exceed its long term liabilities ($440.6M).
Debt to Equity History and Analysis
Debt Level: 6YG has more cash than its total debt.
Reducing Debt: 6YG's debt to equity ratio has reduced from 197.8% to 116.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 6YG has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 6YG is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 36.1% per year.